EMA Reviews Public Communication Strategy
The EMA has unveiled a new survey to assess how its communication strategy to the general public is perceived and valued by its stakeholders.
The European Medicines Agency (EMA) has unveiled a new survey to assess how its communication strategy to the general public is perceived and valued by its stakeholders.
The survey addresses how the agency communicates to the general public, and focuses on information made public mainly through the EMA website, including press releases and news announcements. EMA plans to distribute the results of the analysis.
“This will provide valuable feedback to help us to better plan and carry out our communication activities,” noted Monika Benstetter, Head of Media and Public Relations at EMA. “This is the second communications survey, the first having taken place in 2015, and it is anticipated that this exercise will be repeated every two years.”
The survey will be open until May 31, 2017, and Benstetter estimates that it should take you no longer than 10 minutes to complete. To access it, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
